Dr David Propper

Senior Lecturer
Group Leader
Research Focus

My focus is detailed translational trials in pancreatic cancer, with a focus on targeting the tumour microenvironment. These approaches include immune therapies, stem cell, stromal and vascular targeting. A major emphasis is on GCP level detailed biomarker studies in early phase trials.

Key Publications

Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective randomised double-blind multicentre phase 2 trial. Lancet Oncol (2017) 18 486-499. PMID: 28259610

Remodelling of microRNAs in colorectal cancer by hypoxia alters metabolism profiles and 5-fluorouracil resistance. Hum Mol Genet (2017) 26 1552-1564. PMID: 28207045

Phase II study of TP300 in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma. BMC Cancer (2016) 16: 779.

Relative telomere lengths in tumor and normal mucosa are related to disease progression and chromosome instability profiles in colorectal cancer. Oncotarget (2016) 7 36474-36488. PMID: 27167335

Major Funding
  • CRUK
  • Stand Up To Cancer/Lustgarten Foundation
  • MRC
  • Barts Charity
Research

I am a Senior Lecturer and Consultant Medical Oncologist based at Barts Cancer Institute and St Bartholomew’s Hospital.

I am lead for GI trials with a focus on pancreatic cancer. I work with scientists within the BCI in crosscutting themes targeting the tumour microenvironment. These approaches include immune therapies, stem cell, stromal and vascular targeting. A major emphasis is on GCP level detailed biomarker studies in early phase trials. In the laboratory, we use a variety of preclinical models and clinically derived material to study effects of therapies in pancreatic cancer.

Major Funding
  • CRUK
  • Stand Up To Cancer/Lustgarten Foundation
  • MRC
  • Barts Charity